Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Andrew Victor Biankin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-0362-5597; OpenAlex author ID A5089677089. Sources: OpenAlex.

Their work

Papers
103 (first author 6, last author 18)
Trials
0
Grants
0
Labs led
2
Collaborators
331
Papers, trials and grants by year

2011: 3 papers · 2012: 5 papers · 2013: 3 papers · 2014: 9 papers · 2015: 11 papers · 2016: 9 papers · 2017: 10 papers · 2018: 6 papers · 2019: 6 papers · 2020: 7 papers · 2021: 9 papers · 2022: 7 papers · 2023: 7 papers · 2024: 3 papers · 2025: 4 papers · 2026: 4 papers

Papers 50 of 103

  1. Clinical and molecular landscape of surgically resected early onset pancreatic cancer. Co-author DOI 10.1093/bjs/znag032↗
  2. Deep Learning of Histopathology Predicts Outcomes After Surgery for Pancreatic Cancer. Co-author DOI 10.1200/cci-25-00268↗
  3. Multi-modal digital twin model outperforms conventional biomarker stratification in pancreatic cancer. Last author DOI 10.3389/frai.2026.1873681↗
  4. Pulsed priming with the FAK inhibitor narmafotinib enhances both gemcitabine/Abraxane and FOLFIRINOX chemotherapy response in pancreatic cancer Co-author DOI 10.64898/2026.07.23.740234↗
  5. Sequential ATR and PARP inhibition overcomes acquired DNA damaging agent resistance in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41416-025-03051-z↗
  6. Improving outcomes of patients with pancreatic cancer. Last author DOI 10.1038/s41571-025-01019-9↗
  7. Jorunnamycin A induces apoptosis in pancreatic ductal adenocarcinoma cells, spheroids, and patient-derived organoids by modulating KRAS-mediated survival pathw… Co-author DOI 10.1038/s41598-025-95766-5↗
  8. Mapping the Proteomic Landscape of Pancreatic Cancer: Prognostic Insights and Subtype Stratification. Co-author DOI 10.1158/2767-9764.crc-25-0229↗
  9. Roflumilast inhibits tumor growth and migration in STK11/LKB1 deficient pancreatic cancer. Co-author DOI 10.1038/s41420-024-01890-y↗
  10. Disruption of the pro-oncogenic c-RAF-PDE8A complex represents a differentiated approach to treating KRAS-c-RAF dependent PDAC. Co-author DOI 10.1038/s41598-024-59451-3↗
  11. nSMase2-mediated exosome secretion shapes the tumor microenvironment to immunologically support pancreatic cancer Co-author DOI 10.1101/2024.09.23.614610↗
  12. A systematic review and meta-analysis of germline BRCA mutations in pancreatic cancer patients identifies global and racial disparities in access to genetic te… Co-author DOI 10.1016/j.esmoop.2023.100881↗
  13. Treatment of pancreatic cancer in 2022. First author DOI 10.1017/pcm.2023.2↗
  14. A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancer. Co-author DOI 10.1038/s43018-023-00614-y↗
  15. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000005050↗
  16. FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2022-327927↗
  17. Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake. Co-author DOI 10.1177/17588359231189127↗
  18. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  19. ICGC-ARGO precision medicine: familial matters in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(21)00703-8↗
  20. ICGC-ARGO precision medicine: an update on familial matters in pancreatic cancer. Co-author DOI 10.1016/s1470-2045(22)00448-x↗
  21. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  22. Pharmacologic Targeting of TFIIH Suppresses KRAS-Mutant Pancreatic Ductal Adenocarcinoma and Synergizes with TRAIL. Co-author DOI 10.1158/0008-5472.can-21-4222↗
  23. CDK7 inhibition augments response to multidrug chemotherapy in pancreatic cancer. Co-author DOI 10.1186/s13046-022-02443-w↗
  24. Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care. Last author DOI 10.3390/cancers14133239↗
  25. Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. Co-author PMID 36628279↗
  26. Reshaping preoperative treatment of pancreatic cancer in the era of precision medicine. Co-author DOI 10.1016/j.annonc.2020.11.013↗
  27. Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Co-author DOI 10.1038/s41467-021-27099-6↗
  28. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  29. Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward. First author DOI 10.1053/j.gastro.2021.06.080↗
  30. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Co-author DOI 10.1126/sciadv.abh0363↗
  31. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  32. Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis. Last author DOI 10.1200/jco.20.03238↗
  33. Muscle-Derived Cytokines Reduce Growth, Viability and Migratory Activity of Pancreatic Cancer Cells. Co-author DOI 10.3390/cancers13153820↗
  34. Molecular Subtyping and Precision Medicine for Pancreatic Cancer. Co-author DOI 10.3390/jcm10010149↗
  35. An unbiased high-throughput drug screen reveals a potential therapeutic vulnerability in the most lethal molecular subtype of pancreatic cancer. Co-author DOI 10.1002/1878-0261.12743↗
  36. Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2020.05.010↗
  37. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.107625↗
  38. PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer. Co-author DOI 10.1016/j.clon.2019.07.011↗
  39. Pancreatic Cancer: From Genome Discovery to PRECISION-Panc. Co-author DOI 10.1016/j.clon.2019.08.007↗
  40. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  41. Repression of the Type I Interferon Pathway Underlies MYC- and KRAS-Dependent Evasion of NK and B Cells in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-19-0620↗
  42. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Co-author DOI 10.1002/path.5320↗
  43. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Co-author DOI 10.1016/j.cmet.2019.02.001↗
  44. Molecular subtypes of pancreatic cancer. Last author DOI 10.1038/s41575-019-0109-y↗
  45. Different shades of pancreatic ductal adenocarcinoma, different paths towards precision therapeutic applications. Co-author DOI 10.1093/annonc/mdz181↗
  46. Prolactin Promotes Fibrosis and Pancreatic Cancer Progression. Co-author DOI 10.1158/0008-5472.can-18-3064↗
  47. Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. Co-author DOI 10.21037/cco.2019.04.06↗
  48. Chemotherapy and radiotherapy for advanced pancreatic cancer. Co-author DOI 10.1002/14651858.cd011044.pub2↗
  49. ADAM12 is a circulating marker for stromal activation in pancreatic cancer and predicts response to chemotherapy. Co-author DOI 10.1038/s41389-018-0096-9↗
  50. Exome-Wide Association Study of Pancreatic Cancer Risk. Co-author DOI 10.1053/j.gastro.2017.10.015↗

Closest collaborators

The 25 strongest of 331 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. David Kuang-Fu Chang · 55 shared papers, 2011–2026 · strength 4.65
  2. Stephan B. Dreyer · 11 shared papers, 2017–2026 · strength 1.71
  3. Raffaella Casolino · 10 shared papers, 2021–2023 · strength 1.69
  4. Nigel Balfour Jamieson · 14 shared papers, 2014–2026 · strength 1.33
  5. Peter J. Bailey · 16 shared papers, 2014–2022 · strength 1.10
  6. Christian P. Pilarsky · 9 shared papers, 2012–2025 · strength 1.06
  7. Amber L. Johns · 17 shared papers, 2012–2023 · strength 1.02
  8. Sean Michael Grimmond · 22 shared papers, 2012–2021 · strength 0.95
  9. Fieke E. M. Froeling · 5 shared papers, 2021–2026 · strength 0.90
  10. Colin J. McKay · 8 shared papers, 2014–2026 · strength 0.88
  11. Marina Pajic · 20 shared papers, 2011–2021 · strength 0.87
  12. Steve Gallinger · 6 shared papers, 2017–2026 · strength 0.84
  13. Aldo Scarpa · 9 shared papers, 2014–2023 · strength 0.83
  14. Jennifer P. Morton · 11 shared papers, 2014–2022 · strength 0.78
  15. Anthony James Gill · 13 shared papers, 2012–2023 · strength 0.70
  16. Owen James Sansom · 9 shared papers, 2014–2022 · strength 0.66
  17. Jaswinder Singh Samra · 11 shared papers, 2012–2023 · strength 0.65
  18. Debabrata Mukhopadhyay · 4 shared papers, 2021–2025 · strength 0.61
  19. Michèle Milella · 5 shared papers, 2021–2022 · strength 0.60
  20. Talia Golan · 4 shared papers, 2021–2023 · strength 0.59
  21. Robert Grützmann · 5 shared papers, 2012–2025 · strength 0.58
  22. Salvatore Paiella · 4 shared papers, 2021–2023 · strength 0.55
  23. Adnan M. Nagrial · 12 shared papers, 2012–2020 · strength 0.55
  24. Robert C. Grant · 3 shared papers, 2018–2026 · strength 0.54
  25. Claudio Bassi · 5 shared papers, 2016–2023 · strength 0.54

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.